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Abstract
Noninvasive imaging of differences between the
molecular properties of cancer and normal tissue has
the potential to enhance the detection of tumors.
Because overexpression of endogenous transferrin
receptor (TfR) has been qualitatively described for
various cancers and is presumably due to malignant
transformation of cells, TfR may represent a suitable
target for application of molecular imaging technolo-
gies to increase detection of smaller tumors. In the
work reported here, investigation into the biology of
this receptor using electron microscopy has demon-
strated that iron oxide particles targeted to TfR are
internalized and accumulate in lysosomal vesicles
within cells. Biochemical analysis of the interaction
of imaging probes with cells overexpressing the TfR
demonstrated that the extent of accumulation, and
therefore probe efficacy, is dependent on the nature of
the chemical cross-link between transferrin and the
iron oxide particle. These data were utilized to design
and synthesize an improved imaging probe. Experi-
ments demonstrate that the novel magnetic resonance
imaging (MRI) probe is sensitive enough to detect
small differences in endogenous TfR expression in
human cancer cell lines. Quantitative measurement of
TfR overexpression in a panel of 27 human breast
cancer patients demonstrated that 74% of patient
cancer tissues overexpressed the TfR and that the
sensitivity of the new imaging agent was suitable to
detect TfR overexpression in greater than 40% of these
cases. Based on a biochemical and cell biological
approach, these studies have resulted in the synthesis
and development of an improved MRI probe with
the best in vitro and in vivo imaging properties re-
ported to date.
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Introduction
Amajor goal for the field of molecular imaging has been real-
time noninvasive detection of gene expression in vivo. A
significant amount of effort in this field has been directed at
imaging transgenes, with cDNAbeing added to the complement
of normally expressed genes in target tissues (for review, see
Ref. [1]). Following gene transfer, specific probes designed to
exploit the unique characteristics of transferred gene products
are used to report on transgene expression. Examples of such
imaging successes include luciferase (optical imaging [2,3]),
the thymidine kinase of herpes simplex virus I (HSV-TK; nuclear
imaging [4]), and b-galactosidase (magnetic resonance imag-
ing, MRI [5]). Many of the achievements of these strategies
have been due to the use of transgenes that have little or no
expression in the targeted tissues, or even the species under
investigation. Therefore, translations of these imaging suc-
cesses into common utility require pairing of the technologies
with transgenic animals or gene therapy.
On the other hand, significant accomplishments have also
been demonstrated for imaging endogenous gene products,
whose expression and/or activity is altered in the disease state
(for review, see Ref. [6]). In our own work using MRI to non-
invasively image transgene expression in vivo, we have
attempted to merge transgene and endogenous gene imaging
approaches. Utilizing the engineered transferrin receptor (ETR)
derived from an endogenous gene, the transferrin receptor
(TfR), we have relied on the resolution of MRI and ETR-
targeted iron oxide probes to image the expression of the
transferred ETR [7–9]. This version of the receptor is identical
at the protein level but lacks cis-acting RNA elements, thus
allowing constitutively high levels of TfR protein expression.
This approach has demonstrated the utility of MRI to image
transgene expression and has also shown that it is feasible to
image relative differences in receptor expression [7,9,10].
These findings have suggested a number of possibilities for
application of MRI to monitor disease-specific changes in
endogenous TfR expression. For example, overexpression of
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endogenous TfR has been qualitatively described for various
cancers [11–15], presumably due to malignant transforma-
tion of normal cells, and therefore TfR may represent a
suitable target for early detection of cancer.
Our previous work [7–9] demonstrating the feasibility of
imaging the TfR also highlighted the need for synthesis of
probes with improved sensitivity to image changes in en-
dogenous TfR expression. The goal of this study was to
utilize the biochemical analysis of transferrin (Tf)– iron
oxide–cell interactions to improve the synthesis and design
of a more sensitive MR probe for the TfR. In order to design
a more efficacious MRI probe, we have 1) investigated in
detail the biology of TfR-targeted iron oxide imaging probes;
2) applied this knowledge to synthesize more efficacious
probes; 3) demonstrated the utility of the new probes; and
4) validated the utility of the TfR to be an informative
imaging marker for human breast cancer. Specifically, the
current work demonstrates that: 1) iron oxide particles are
internalized and sorted to lysosomal vesicles within cells; 2)
the chemical cross-link used for the covalent binding of Tf
and iron oxide particles has an influence on the biology of
particle internalization; 3) the nature of cross-linking can
improve the efficacy of the probe for TfR/ETR imaging
in vitro and in vivo; and 4) the improved probe can be
utilized to image small differences in endogenous TfR
expression in human cancer cell lines. Finally, to show the
utility of endogenous TfR as a marker for human cancers,
the level of endogenous TfR overexpression was quantified
in over 25 human breast cancer patients, demonstrating
that a large proportion of these patients significantly over-
expresses endogenous TfR in their cancer tissues.
Experimental
Synthesis of TfR-Targeted Iron Oxide Particles
Monocrystalline iron oxide nanoparticles were prepared
through the reaction of iron salts with ammonium hydroxide
in the presence of T10 dextrans [16]. The dextrans were then
modified in the presence of epichlorohydrin according to
previous reports to yield cross-linked iron oxide nanopar-
ticles (CLIO-10). CLIO was finally treated with ammonia and
dialyzed as described, in order to obtain reactive groups for
the covalent binding of bifunctional linker reagents [17].
The conjugation of CLIO-NH2 and human diferric Tf (Sig-
ma, St. Louis, MO) using the linker reagent N-succinimidyl 3-
(2-pyridyldithio)propionate (SPDP; Molecular Biosciences,
Boulder, CO) leads to a disulfide bond (Tf-SS-CLIO) [8],
whereas employing the linker reagent succinimidyl iodoace-
tate (SIA; Molecular Biosciences) forms a more stable cova-
lent linkage through a thioether bond (Tf-SC-CLIO) [18]. The
synthesis of Tf-SS-CLIO and Tf-SC-CLIO is summarized
in Figure 1 and has been described before [8,18]. Unreacted
Tf-SH was separated from Tf-SS-CLIO and Tf-SC-CLIO
using magnetic columns (Macs separation columns; Miltenyi
Biotech, Auburn, CA) equilibrated with phosphate-buffered
saline (PBS; pH 8). To calculate the number of Tf molecules
per particle, the protein (BCA; Pierce, Rockford, IL) and iron
concentrations of purified material were determined [10,19]
and a mean of 2064 iron atoms per particle was assumed
[19]. The r1 and r2 relaxivities were measured using a 0.47 T
tabletopminispectrometer, as described [19]. The conjugates
were stored in PBS, pH 8, either at 4jC, or were shock-frozen
in liquid nitrogen and kept at 20jC.
Figure 1. Reaction schemes for the synthesis of Tf-SS-CLIO and Tf-SC-CLIO.
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Cell Culture
Wild-type rat 9L gliosarcoma cells (Brain Tumor Research
Center, San Francisco, CA) and rat 9L gliosarcoma cells
stably transfected with an altered form of the human trans-
ferrin receptor ETR (9L3.9 and 9L4.2 cells) [7,10] were grown
in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro;
Mediatech, Washington, DC) containing 10% fetal bovine
serum (FBS; Cellgro). Transfected cells were periodically
passaged in the presence of G418 to assure the integrity of
plasmid expression [10]. Breast carcinoma cell lines BT20,
MCF7, BT549, and HBL100 as well as the nontumorigenic
cell line MCF10A derived from fibrocystic disease were
obtained from the ATCC (Manassas, VA) and kept in culture
as recommended. In all cell cultures, the medium was
changed every third day and cells were split at a confluence
of about 80%.
Analysis of TfR Expression by Western Blotting
Samples of 106 cells were heated for 5 minutes in 80 ml of
sodium dodecyl sulfate (SDS) sample buffer containing 5%
b-mercaptoethanol and then passaged through a 28-gauge
needle. Equal amounts (20 ml/lane) were separated on 8%
SDS polyacrylamide gels [20] and transferred onto Hybond-P
membranes (Amersham Biosciences, Piscataway, NJ). Im-
munoblot analyses were performed using an ECL kit (Amer-
sham Biosciences) according to the manufacturer’s
instructions. In brief, after blocking with 5% dry milk in
TBS-T [20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 0.1%
Tween 20], the membranes were incubated for 2 hours at
room temperature with the primary anti –TfR antibody
(H68.4; Zymed Laboratories, Inc., San Francisco, CA) diluted
1:500 in TBS-T containing 5% dry milk. After washing in
TBS-T, the membranes were incubated for 1 hour at room
temperature with horseradish peroxidase–conjugated anti–
mouse secondary antibodies (Sigma) at a concentration of
1:10000 in TBS-T containing 5% dry milk. The membranes
were then washed thoroughly in TBS-T, swirled for 1 minute
in ECL reagents, and exposed to photographic films. For
assessment, films were scanned and the number of pixels in
regions of interest was quantified using NIH Image 1.6.
Because no preflashing of the films was carried out, the data
can only be described as semiquantitative. Reported data
have been corrected for background intensities.
Competition and Uptake Studies with Radioactively
Labeled Tf
Tf was radiolabeled with Na125I in the presence of
IodoGen (Pierce). Unbound iodide was removed by centrif-
ugation through Bio-Gel P6 spin columns (Bio-Rad, Hercu-
les, CA). Cells were plated at a density of 105 cells/well onto
24-well plates (Falcon; Becton Dickinson, Lincoln Park, NJ).
One day (9L3.9) or 2 days (BT20, MCF7, BT549, HBL100,
and MCF10A) later, different concentrations of unlabelled
diferric Tf, Tf-SS-CLIO, or Tf-SC-CLIO (2.5 nM–2.5 mM Tf
in DMEM) were added immediately prior to the addition of
[125I]Tf (0.25 nM in DMEM) and cells were incubated for 1
hour at 37jC. The cells were then washed three times with
Hanks’ balanced salt solution (HBSS; Bio-Whittaker, Wal-
kersville, MD) and detached with trypsin (0.05% trypsin,
0.5 mM ethylenediaminetetra-acetic acid). The entire con-
tents of the wells were counted in a g-counter (1282
Compugamma CS; LKB Wallac, Turko, Finland) to deter-
mine cell-associated radioactivity.
Stability of TfR-Targeted Iron Oxide Particles in Cell Culture
9L3.9 cells were plated in 24-well dishes at a density of
105 cells/well. Twenty-four hours later, cells were washed
with HBSS and incubated with Tf-SS-CLIO or Tf-SC-CLIO
(0.375 mM/ml Tf) in DMEM alone or DMEM containing the
metabolic inhibitors 50 mM 2-deoxy-D-glucose, 1% Na-
azide, and 10 mM KCN [21]. Both conjugates were also
incubated in cell-conditioned DMEM (conditioned for
6 hours), or in fresh DMEM. All incubations were carried
out for 6 hours at 37jC. SDS polyacrylamide gel electropho-
resis [20] was used to determine the integrity of the different
conjugates. Samples were mixed with nonreducing SDS
sample buffer. Where reducing conditions were used, 5%
b-mercaptoethanol was added to the SDS sample buffer and
samples were heated at 95jC for 5 minutes. Nonreduced
samples were not subjected to heating as controls demon-
strated that this had no effect on the integrity of the conjugate
(data not shown). Three micrograms of protein was loaded
per lane and separated using a 10% SDS polyacrylamide
gel. Gels were run at a constant voltage of 120 V and stained
with Coomassie brilliant blue R-250.
Electron Microscopy (EM)
One day prior to treatments, 9L3.9 cells were seeded at a
density of 106 cells per 10-cm culture dish. Cells were then
incubated in the indicated medium for 2, 24, and 48 hours,
respectively, and were washed three times with cell-condi-
tioned medium. Afterward, cells were fixed by adding to the
culture medium an equal volume of 0.2 M PHEM buffer
(120mMPIPES, 50mMHEPES, 4mMMgCl2, 20mMEGTA;
pH 6.9) containing 0.4% paraformaldehyde and 2% glutaral-
dehyde. After fixation for 1 hour at room temperature, cells
were rinsed in PBS, scrapedwith a rubber policeman into 5ml
of PBS containing 1% gelatin, and pelleted at 700 rpm for
10 minutes (Sorvall 7 RT; Kendro Laboratory Products, New-
town, CT). The cells were resuspended in 2 ml of PBS,
pelleted again at 700 rpm for 10 minutes, and taken up into
storage buffer (0.5% paraformaldehyde in 0.1 M PHEM
buffer). For immunogold labeling, the buffer was replaced
byPBS containing 20mMglycine. Cells were then embedded
in 12%gelatin in phosphate buffer, infiltrated for 4 hours in 2.3
M sucrose in the same buffer, and frozen in liquid nitrogen.
Ultrathin sectioning (60 nm) and immunogold labeling were
carried out as described elsewhere [22]. Anti–human TfR
antibody (H68.4) was purchased from Zymed Laboratories,
Inc. The immunogold-labeled sections were incubated for 5
minutes on a drop of distilled water containing 2% methylcel-
lulose and 0.4% uranyl acetate, after which they were air-
dried. In some experiments, cell contrast was reduced in
order to distinguish the electron-dense CLIO particles from
the surrounding cytoplasm. In those cases, the immunogold-
labeled sections were incubated for 5 minutes on a drop of
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distilled water containing 2% methylcellulose and 0.4% ura-
nyl acetate. Then, the sections were rinsed for 10 minutes on
a drop of distilled water, put on a drop of 2% methylcellulose
for 5 minutes, and air-dried. The sections were examined in
the transmission electron microscope at 80 kV and photo-
graphed at a magnification of  21,000.
MRI In Vitro
Concentration-dependent cell association, time course, and
washout studies To determine the cellular association of
Tf-targeted CLIO conjugates, 105 cells were seeded per well
onto 24-well plates 1 day (9L3.9) or 2 days (BT20, MCF7,
BT549, HBL100, and MCF10A) before the experiment. Cells
were then incubated for 2 hours in DMEM, 10% FBS con-
taining either Tf-SS-CLIO or Tf-SC-CLIO at increasing con-
centrations (1.8 mM–3.6 mM iron). For time-dependent
studies, 3.5  104 cells (9L3.9) were seeded onto 24-well
plates. Twenty-four hours later, the cells were incubated for
2, 8, 24, or 48 hours with either Tf-SS-CLIO or Tf-SC-CLIO
(3.6 mM iron) in DMEM, 10% FBS. For washout experi-
ments, cells (9L3.9) were loaded for 18 hours with Tf-SS-
CLIO or Tf-SC-CLIO (3.6 mM iron) in DMEM, 10% FBS,
washed once with HBSS, and the medium was changed to
fresh DMEM, 10% FBS. Cells were harvested at time zero
(immediately after washing) and 2, 8, and 24 hours after
cessation of loading. To control for receptor specificity, cells
were also incubated with nonconjugated CLIO (3.6 mM iron)
as well as with Tf-SS-CLIO or Tf-SC-CLIO (3.6 mM iron) in
the presence of a 10-fold excess of nonconjugated Tf.
Nonspecific binding of the probes to culture dishes was
measured by the incubation of probe in the absence of cells.
Cell harvesting All incubations were carried out at 37jC
and at the end of the respective incubation times and
conditions, cells were washed three times with HBSS
and then lysed in 60 ml of PBS, pH 8, containing 1% Triton
X-100. Lysates were transferred to the wells of 384-well
plates and centrifuged at 700 rpm for 2 minutes (Sorvall 7
RT; Kendro Laboratory Products) to remove any air bub-
bles trapped at the bottom of the wells. Purified CLIO
particles (0.9–18 mM iron/ml PBS, pH 8, 1% Triton X-
100) were also included in the dish as standards.
MR measurements MRI was performed using a clinical
1.5 T superconducting magnet (Signa 5.0; GE Medical Sys-
tems, Milwaukee, WI) equipped with a standard 3- or 5-in.
surface coil. MRI and postprocessing of the data have been
described before [18]. In brief, the imaging protocol consisted
of a spin echo sequence (TR 3000 milliseconds, variable TE
15–1200 milliseconds; total of 20–24 echo times). At a field
of view (FOV) of 8 cm  8 cm, a 256  256 imaging matrix,
and a slice thickness of 1.5 mm, each voxel had a size of
0.146 mm3. The obtained MR images were processed on a
personal computer using MATLAB 6.0 (The MathWorks,
Natick, MA). Signal intensities of each single voxel were
plotted against the various echo times (TEs) and curve fitting
for exponential decay allowed the calculation of T2 relaxation
times according to the following equation: SI ¼ AeðTe=T2Þ þ
B, with SI = signal intensity, TE = echo time, A = amplitude,
and B = offset. For the automatic measurement of the
average T2 relaxation time of each well, the software IPLab
3.5.2 (Scanalytics, Fairfax, VA) was used and the data were
exported to a spreadsheet [18].
MRI In Vivo
Clones of 9L gliosarcoma cell lines differing in their expres-
sion of the TfR (9L3.9 and 9L4.2) were cultivated in 175-cm2
culture flasks [7]. Cells were detached, washed with HBSS,
and resuspended in HBSS at a concentration of 6  104
cells/ml. Nude mice (nu/nu; Fisher Scientific, Agawam, MA)
were anesthesized by intraperitoneal injection of ketamine
(80 mg/kg; Parke-Davis, Morris Plains, NJ) and xylazine (12
mg/kg; Miles, Shawnee Mission, KS) and tumor cells were
implanted subcutaneously at the base of the ear (n = 8).
Based on preliminary studies, implantation at the base of
the ears was chosen as the best model because: 1) tumors
were highly vascularized; 2) symmetric placement was easily
achieved; and 3) tumors grew at a similar rate, reaching a
comparable size sufficient for MRI. MR examinations were
performed using a 1.5-T MR imager (Signa 5.0; GE Medical
Systems) employing a special 1.5-in. surface coil (Nova
Medical, Inc., Wakefield, MA). All sequences had the same
resolution with a FOV of 5 cm  2.5 cm (Phase FOV 0.5), a
256  160 imaging matrix, and a slice thickness of 1.5 mm.
Localizers in all three planes allowed the exact placement of
the imaging slices. The intravenous dose of contrast agent,
15 mg iron/kg body weight, was determined empirically. The
spin echo sequences used were: 1) TR 300 milliseconds, TE
11 milliseconds, four NEX, 1:40 minutes; and 2) TR 2000
milliseconds, TE 15, 25, 30, 45, 50, 60, 75, and 100 milli-
seconds, one NEX, 6:08 minutes. For Fast Spin Echo
Inversion Recovery, the following parameters were used:
TR 4850 milliseconds, effective TE 36 milliseconds, TI
150 milliseconds, two NEX, 1:42 minutes.
Five days after implantation, MR images were obtained
and contrast probes were administered by tail vein injection
(Tf-SC-CLIO, n = 4, or nonconjugated CLIO, n = 4). MRI was
repeated 24, 48, and 72 hours after contrast agent. T2 maps
were calculated using MATLAB 6.0, as previously described.
After the MRI examinations, animals were kept alive for
another week to harvest enough tumor tissues for the anal-
ysis of TfR expression by Western blotting. Under general
anesthesia, mice were sacrificed by lethal intravenous injec-
tion of sodium pentobarbital (200 mg/kg; Anpro, Arcadia,
CA). Each tumor was directly transferred into 3 ml of ice-cold
MES buffer (0.1MMES, 1mMEGTA, 0.5mMMgCl2; pH 6.5)
and homogenized using a glass Teflon homogenizer. After
centrifugation for 20 minutes at 12,000 rpm (Sorvall, SS 34
Rotor; Kendro Laboratory Products), the supernatants were
collected and centrifuged for 1 hour at 26,000 rpm (Ti 45
Rotor; Beckman, Columbia, MD). Each resulting pellet was
resuspended in 150 ml of MES buffer. The protein content was
determined using a BCA Assay (Pierce), all samples were
diluted to a protein concentration of 2.7 mg/ml, and mixed 1:2
with reducing SDS sample buffer. Forty microliters per lane
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were separated by SDS gel electrophoresis and the TfR
expression was analyzed by Western blotting (see above).
Laser Capture Microdissection and Real-Time Quantitative
Polymerase Chain Reaction (RT-Q-PCR)
For procured samples, we have used laser capture micro-
dissection with a PixCell II LCM Microscope (Arcturus Engi-
neering, Mountain View, CA) to collect normal and cancer
cells from fresh frozen tumor sections derived from patient
samples. RNA was then isolated from dissected cells, lin-
early amplified, and expression of the TfR mRNA was
quantified by RT-Q-PCR. Procedures are detailed in Sgroi
et al. [23]. All human samples were obtained and experi-
ments were conducted with IRB-approved protocols.
Results
Type of Conjugation Affects Cellular Uptake of
Contrast Agents
Previously, we described a model in which overexpression of
the engineered version of the TfR (ETR) in cells results in
binding and presumably internalization of a derivatized form
of holotransferrin. In those studies, it was demonstrated that
the proposed model is valid for noninvasive imaging of ETR
transgene expression by MRI using Tf conjugated with iron
oxide nanoparticles [7,8,10]. In order to better understand
the underlying biological mechanisms resulting in improved
detection by MRI and to apply this knowledge to image
changes in endogenous TfR expression, the molecular
events that occur upon interaction of derivatized Tf with cells
were investigated. For these studies, two different conjuga-
tion schemes were used. The first formed disulfide linkages
between Tf and iron oxide particles [8] and the second
formed thioether bonds [18]. Both conjugation procedures
are summarized in Figure 1.
First it was determined if different conjugation strategies
affected the affinity of the Tf– iron oxide molecules for the
receptor. Previous studies showed a significant increase in
affinity with altered linker chemistry and length [8]. However,
here, little difference was found in the affinity of Tf-SS-CLIO
and Tf-SC-CLIO for TfR. Normalized to total particles pres-
ent, the IC50 was 84 ± 5.9 nM for Tf-SS-CLIO and 126.5 ±
19.5 nM for Tf-SC-CLIO. Normalized to Tf molecules, the
IC50 of Tf-SS-CLIO is 306.8 ± 21.2 nM (see Ref. [8]) and the
IC50 of Tf-SC-CLIO is 184.1 ± 28.4 nM. The magnetic
properties of Tf-SS-CLIO and Tf-SC-CLIO were also very
similar and are summarized in Table 1.
However, as expected, the chemical stability of the linkers
differed. SDS gel electrophoresis revealed that the Tf-SC-
CLIO conjugate, unlike the Tf-SS-CLIO conjugate, remained
intact following treatment with 5% b-mercaptoethanol (Ref.
[8] and data not shown). The different chemical stability of the
linkers affected the interaction of the conjugates with cells. In
comparison to the controls, increased amounts of free Tf
were detected after incubation of Tf-SS-CLIO with either
tissue culture cells or cell-conditioned DMEM, the latter
suggesting that disulfide bond cleavage could occur in the
absence of cells (Figure 2, right panel). In contrast, no Tf was
liberated when incubations were performed with Tf-SC-CLIO
(Figure 2, left panel). For Tf-SS-CLIO, cleavage of the
disulfide bond was also observed after incubation with cells
in the presence of metabolic inhibitors of cellular uptake
(10 mM KCN, 1% Na-azide, and 50 mM 2-deoxy-D-glucose;
see Experimental section), further indicating that cellular
internalization is not required for cleavage of Tf-SS-CLIO
(data not shown).
When the cellular uptake of the conjugates was investi-
gated, it was determined that the type of linkage significantly
affected the uptake, but not the efflux, of the Tf-targeted iron
oxide particles. Even though the two conjugates had similar
affinities for the TfR, the concentration dependence and time
course for uptake varied significantly. At both lower concen-
trations (Figure 3A) and at shorter times (Figure 3B), the
extent of cell-associated iron oxide particles (as measured
by MRI) was greater with the more stable probe, Tf-SC-CLIO.
The most significant binding and uptake of both conjugates
were seen in the first 2 hourswith a continuingly higher cellular
accumulation of iron for Tf-SC-CLIO over an extended time
course (Figure 3B). The improved uptake of Tf-SC-CLIO by
cellswasnot due to aneffect of linker chemistry on theefflux of
iron oxide nanoparticles from the cells (Figure 4). Between 2
and 8 hours after incubation with Tf-targeted CLIO, the
washout of iron oxides was complete and reached a plateau
for both conjugates of 41.1 ± 3.7% of starting values.
Analysis of Uptake by EM
The difference in uptake of iron oxide particles depending on
the linker chemistry of the conjugates was also reflected by
EM. Using nanogold-conjugated antibodies specific to struc-
tural markers or the TfR, EM was used to determine the
subcellular location of TfR and CLIO particles. Panel A in
Figure 5 presents the pattern of TfR distribution in 9L3.9 cells
that were not incubated with either of the imaging probes.
Gold particles indicating the location of the TfR are seen in
association with the plasma membrane, coated vesicles,
endosomes, and the Golgi complex. Panels B and C show
that after 2 hours of incubation with Tf-SC-CLIO conjugates,
CLIO particles were often localized within large TfR-positive
structures, characteristic for late endosomes (CLIO particles,
due to their density and size, are readily visible without gold-
conjugated antibodies). After 48 hours of incubation with
Tf-SC-CLIO conjugates, CLIO particles accumulated in
lysosomes (l), as demonstrated in panels D, E, and F (arrow-
heads). In contrast to panels B and C, only small amounts of
gold particles (indicating the presence of TfR) and CLIO
Table 1. Properties of Tf – Iron Oxide Conjugates.
Compound r1
[sec  mM]1
r2
[sec  mM]1
Average Tf
Molecules Per
Particle
Linker
Chemistry
Tf-SS-CLIO
(n = 4)
31.2 ± 0.5 149.1 ± 8.8 3–4 Disulfide
bond
Tf-SC-CLIO
(n = 4)
32.1 ± 2.7 144.0 ± 6.1 1–2 Thioether
bond
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particles were contained in endosomes in panels D, E, and F
(a large translucent endosome can be seen in photo F). From
these data, it would appear that most Tf-SC-CLIO uptake
occurs within the first 2 hours and slows down over time
(Figure 3B). In comparison to the 2-hour time point, the
amount of TfR and CLIO particles in endosomes seen
by EM decreased after a continuous 48-hour incubation with
Tf-SC-CLIO. Because no signs of iron toxicity were noted, it is
Figure 2. Stability of MRI probes. SDS gel electrophoresis was used to determine the stability of the conjugates to different treatments. Conjugates were incubated
in tissue culture dishes containing DMEM and cells, cell-conditioned DMEM, or DMEM alone. Following incubation, a portion of the medium was subjected to
electrophoresis. Lane 1 is holotransferrin for reference and lane 8 is medium from a well that contained cells and DMEM, but was not incubated with probe.
Figure 3. Cell-associated iron after incubation with Tf-SS-CLIO or Tf-SC-CLIO. Cells (9L3.9) were incubated with increasing concentrations of the two conjugates
for 2 hours (A) or with saturating concentrations (3.6 mM iron) for the indicated times (B). Following incubations, cells were washed with HBSS, lysed, and imaged
by MRI. Iron contents were calculated based on standards of purified CLIO and expressed in relation to the highest iron concentration found in each experiment
(maximum concentration or maximum time). Data are presented as the mean and standard deviation of quadruplicates.
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likely that the potential explanation for this finding is that TfR
recycling is interrupted, which eventually leads to a depletion
of TfR and therefore a decreased uptake of Tf-targeted CLIO.
Cells challenged with Tf-SS-CLIO showed overall a very
similar pattern of TfR and CLIO distribution, but a consider-
ably smaller number of internalized CLIO particles than cells
challenged with Tf-SC-CLIO (data not shown). The relative
amounts of internalized CLIO particles were estimated by EM
after incubation with probes and are as follows: Tf-SC-CLIO
(2 hours), Tf-SC-CLIO (48 hours), Tf-SS-CLIO (2 hours),
Tf-SS-CLIO (48 hours), 20:30:5:10, respectively.
Imaging Differences in TfR Expression In Vitro and In Vivo
The Tf-SC-CLIO probe was shown to have a better ability to
image TfR expression by MRI. In 9L3.9 cells incubated with
Tf-SC-CLIO, changes in T2 relaxation times were easily
detected at 90 mM iron compared to 900 mM iron for the
Tf-SS-CLIO probe (Figure 6). To further demonstrate the
utility of this probe, MRI was used to measure differences in
ETR/TfR levels in vivo. Bilateral tumors with a low (9L4.2)
and a high (9L3.9) expression of the TfR [7] were grown at
the base of the ears of nude mice. Figure 7 shows the T2
maps of the tumors of a representative animal superimposed
with a proton-weighted MR image. MRI before contrast agent
revealed no difference. However, after intravenous injection
of Tf-SC-CLIO, a corresponding higher accumulation of the
contrast agent in the 9L3.9 tumor led to shorter T2 values
detected by MRI. Seventy-two hours after injection of
15 mg/kg Tf-SC-CLIO, average T2 values were 32.07 ±
5.42 milliseconds (9L3.9) and 46.94±6.43 milliseconds
(9L4.2) (Table 2; Mann-Whitney U-test, P < .005). In control
animals, the injection of nontargeted CLIO resulted in no
differential between the two tumors at 72 hours [9L3.9
(37.17 ± 14.05 milliseconds) and 9L4.2 (38.42 ± 9.23 milli-
seconds), Table 2].
Imaging Differences in Endogenous TfR Expression
The next step was to investigate the feasibility and utility of
MRI of endogenous levels of TfR expression after incubation
with Tf-SC-CLIO. Levels of human TfR expression were
measured in a panel of human breast cancer cell lines by
Western blot and assessed in relation to the cell line with the
highest expression, BT549 cells. All of the other malignant
cell lines expressed two- to four-fold less TfR than BT549
cells (BT20, 2.9-fold less; MCF7 and HBL100, 3.4-fold less).
The benign cell line, MCF10A, expressed much less TfR
(118-fold less) than BT549 cells. Using these same cell lines,
it was determined if these relative differences in TfR expres-
sion could be detected using Tf-SC-CLIO and MRI. The
results showed a good linear correlation between the level
of TfR measured by Western blot and the amount of cell-
associated iron for all the cells except HBL-100 cells (corre-
lation coefficient r 2 = 0.94 ± 0.07; Figure 8). These data were
confirmed by comparing the binding/uptake of [125I ]-Tf to the
level of TfR measured by Western blot demonstrating a
similarly high degree of correlation for MCF7, BT549, and
MCF10A cells (r 2 = 0.99 ± 0.001). Relative to BT549 cells,
HBL-100 cells had less receptor but equal iron accumulation.
These data point out that MR assessment of iron levels
measures a complex biology encompassing multiple compo-
nents including receptor levels and receptor activity, andmay
not be a measure of absolute receptor levels in all cases.
TfR Is an Attractive Target in Human Breast Cancers
To determine if the TfR would be an informative marker for
human cancers, the extent of TfR overexpression in human
breast cancer tissues was compared to nonmalignant breast
tissues from the same patients. Using laser capture micro-
dissection, matched normal and tumor tissues were isolated
from27 individual breast cancer patients, yielding 27 samples
of normal breast ductal tissue, 22 invasive ductal carcinoma
samples, and 17 samples of ductal carcinoma in situ (DCIS).
RNA was isolated and amplified as described. Because the
correlation between TfR mRNA and TfR receptor protein
levels is well documented [24,25], we utilized RT-Q-PCR to
measure the level of TfR overexpression in the patient panel.
Approximately 74% of patient cancer samples overex-
pressed the TfR and, of these, 41% overexpressed the TfR
five-fold or greater, a difference that has been demonstrated
here to be measurable by MRI (Figure 9). Within this group,
DCIS showed overexpression of the TfR in 35% of the
samples, whereas 45% of invasive breast cancers had a
five-fold or greater overexpression of TfR.
Discussion
The widespread use of early screening has the potential
to reduce the risk of dying from cancer. However, the
Figure 4.Washout of cell-associated iron oxide particles after incubation with
Tf-SS-CLIO or Tf-SC-CLIO. Cells (9L3.9) were incubated with saturating
concentrations (3.6 mM iron) of either conjugate for 18 hours, then washed
with HBSS, and incubated with fresh medium. At the indicated times, cells
were again washed with HBSS, lysed, and imaged by MRI. Iron contents
were calculated based on standards of purified CLIO and expressed as
a percentage of the highest iron concentration found after incubation with
Tf-SS-CLIO or Tf-SC-CLIO, respectively. Data are presented as the mean
and standard deviation of quadruplicates.
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sensitivity of screening technologies is limited and early
detection of cancer still presents an important diagnostic
challenge. Detection of malignant tumor cells in a back-
ground of normal/hyperplastic benign tissues is often based
on differences in physical properties between tissues, which
are frequently minimal (e.g., proton relaxation times, X-ray
absorption, ultrasound scattering), resulting in low contrast
resolution (i.e., small tumors are not detectable). To enhance
detection of small tumors, our laboratory is developing the
concept of using MRI to detect the differences in molecular
properties between cancer and normal tissues that arise as a
result of malignant transformation.
In the studies presented here, the feasibility of using MRI
to image endogenous TfR overexpression in cancer cells as
a marker for human breast cancer was tested (Figure 9). The
first step in these studies was to understand the interaction of
the probe and target cells more completely and apply these
findings to develop novel probes that would possess greater
sensitivity for TfR detection. The resulting probe was used to
demonstrate that the small differences in relative expression
of endogenous TfR between normal and diseased tissues
may be detectable using this improved probe. Laser capture
microdissection and RT-Q-PCR allowed us to quantify, for
the first time, the extent of TfR overexpression in a human
patient population and suggests that this target may prove
useful as a marker of breast cancer for MRI.
Our previous work had demonstrated that using a bifunc-
tional linker instead of an oxidation–reduction reaction sig-
nificantly increased the cellular association of Tf-targeted
CLIO [8]. This increase was largely attributable to better
affinity of the probe for the TfR. In the studies described here,
two different linker chemistries were used to uncover that
probe uptake is greater and more rapid when a thioether—
rather than a disulfide—bond was used to conjugate Tf and
CLIO. The greater uptake resulted in better detection by MRI
and was not due to changes in affinity of the probe for TfR or
altered probe efflux from the cells. Therefore, it was hypoth-
esized that linker stability might alter the efficacy of the
imaging probe by changing its cellular internalization and/or
processing. When the biological stability of Tf-SS-CLIO and
Tf-SC-CLIO was examined, the findings corroborated those
of Feener et al. [26] in which disulfide cleavage has been
demonstrated to take place at the cell surface, rather than in
endosomes. The disulfide bond was labile upon 1) interac-
tion of probe with cells even in the presence of metabolic
inhibitors, or 2) after incubation with cell-conditioned medi-
um, indicating that cleavage of Tf-SS-CLIO occurs in the
culture medium and/or on the cell surface.
The improved stability of the Tf-SC-CLIO probe is prob-
ably directly responsible for the increased cellular uptake.
Our data comparing the two probes suggest that cleavage of
the disulfide bond releases ‘‘free’’ CLIO from Tf, which is
poorly internalized [7–9], leading to a decrease in imaging
sensitivity for the Tf-SS-CLIO probe. Furthermore, these
studies are in agreement with other related studies that used
TfR to introduce diagnostic or therapeutic agents into cells
and found that the stability of the chemical linkage between
Tf and the agent often has a major influence on the amount
Figure 6.MRI after incubation with different concentrations of Tf-SS-CLIO and Tf-SC-CLIO. Cells (9L3.9) were incubated with increasing concentrations of the two
conjugates for 2 hours, washed, lysed, and imaged by MRI. To control for receptor specificity, cells were also incubated with nonconjugated CLIO as well as with
Tf-SS-CLIO or Tf-SC-CLIO in the presence of a 10-fold excess of nonconjugated Tf. Nonspecific binding to the culture plates was measured by incubation of the
probes in wells that did not contain cells. Data are shown as a color map of T2 values.
Figure 5. Analysis of uptake of iron oxide particles by electron microscopy. Results of nontreated 9L3.9 cells (panel A) and cells incubated with Tf-SC-CLIO
(0.9 mM of iron) for 2 hours (panels B and C) or 48 hours (panels D, E, and F) are shown. Ultrathin sections were stained with anti –human TfR antibody conjugated
to 10-nm colloidal gold, incubated with distilled water containing 2% methylcellulose and 0.4% uranyl acetate, and air-dried (panels A and D). In some experiments
(panels B, C, E, and F), cell contrast was reduced by additional rinsing with distilled water and 2% methylcellulose before air drying in order to improve the
discrimination of CLIO particles. Sections were examined by transmission electron microscopy and photographed at a magnification of  21,000 (e = late
endosome, l = lysosome, pm = plasma membrane, n = nucleus, G = Golgi complex, m = mitochondrion, er = endoplasmic reticulum; arrowheads indicate
accumulated CLIO particles). Data demonstrate receptor-mediated accumulation of Tf-CLIO conjugates at early time points followed by a dissociation of the iron
oxide particles from TfR and accumulation of the iron oxides in lysosomal compartments by 48 hours.
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and/or the efficacy of the delivered conjugate [27–29].
Although these data do not rule out the possibility that the
presence of more Tf ligands on the Tf-SS-CLIO (relative to
Tf-SC-CLIO) probe does, in some way, impair its uptake at
the cell surface, the data argue strongly that stable linker
chemistry substantially influences uptake of the Tf-SC-CLIO
over the Tf-SS-CLIO probe.
We were also able to follow the movement of iron oxide
nanoparticles through cells over time using immunogold
EM. These experiments revealed that both the Tf-SS-CLIO
and Tf-SC-CLIO probes did not participate in the same
intracellular pathways as the nonconjugated holotransfer-
rin. In contrast, EM showed that the bulk of both probes
was taken up by a TfR-mediated process, but was then
sorted to lysosomal compartments. Compared to the 2-
hour incubation, EM after 48 hours of constant incubation
with imaging probes showed endosomes that were almost
depleted of TfR and iron oxide particles, and lysosomes
that were full of iron oxide particles. Notably, TfR was not
detectable in the lysosomes, suggesting that either the
receptor detaches from the probe and is sorted to a
Figure 7. Testing the Tf-SC-CLIO conjugate in vivo. Two cell lines expressing either a high (9L3.9 cells) or a low (9L4.2 cells) level of the TfR were implanted
subcutaneously. Five days after implantation, MRI was performed (1.5 T, Signa 5.0, GE, 1.5-in. coil; spin echo sequence, TR 2000 milliseconds, TE 15–100
milliseconds) to generate a precontrast image. Following this precontrast MRI, Tf-SC-CLIO at a dose of 15 mg/kg iron was injected intravenously and MRI was
repeated 24, 48, and 72 hours later. The T2 values of the tumors of a representative animal superimposed with a proton-weighted image are shown. Statistical
analysis of the T2 values of four animals revealed that this difference was significant (nonparametric analysis Mann-Whitney U-test, two-tailed P value < .005).
Table 2. Time Course for T2 Values Measured In Vivo for Tumors.
Tumor (hours) CLIO Tf-SC-CLIO
9L3.9 9L4.2 9L3.9 9L4.2
0 89.97 ± 45.93 84.64 ± 35.62 88.22 ± 31.74 92.66 ± 64.73
24 22.01 ± 4.56 26.76 ± 5.39 25.25 ± 8.83 23.18 ± 9.69
48 27.60 ± 3.99 31.44 ± 3.88 28.95 ± 5.34 36.74 ± 17.51
72 37.17 ± 14.06 38.42 ± 9.23 32.07 ± 5.42 46.94 ± 6.43
Average T2 values from four animals (milliseconds) for tumors were
measured as described in Experimental section. Data are reported as ±
standard deviation.
Figure 8. Determination of TfR expression by Western blotting and cell
association of Tf-SC-CLIO detected by MRI. Cells of breast cancer lines
(BT20, MCF7, BT549, and HBL100) and a benign fibrocystic cell line
(MCF10A) were homogenized and analyzed by Western blotting. After
semiquantitative assessment using NIH image 1.6, TfR expression was
calculated in relation to BT549 cells (red bars). Binding and uptake of Tf-SC-
CLIO by the different cell lines was measured by MRI (blue bars) after
incubation with saturating concentrations of iron (3.6 mm) and determined
based on standards of purified CLIO particles.
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different compartment, or that the receptor is removed by
lysosomal proteases. Evidence for the latter was reported
several years ago by Mellman and Plutner [30] and Mell-
man et al. [31]. Comparing multivalent versus monovalent
ligands for the macrophage Fc receptor, Mellman and
Plutner and Mellman et al. were able to establish that Fc
receptors recycle rapidly in the presence of monovalent
ligands, but were sorted to and destroyed in lysosomes
when cells were treated with multivalent ligands. The
multivalent nature of both imaging probes used in this
study (Table 1) suggests that the probes themselves alter
the processing within the cells, resulting in lysosomal
retention of the nanoparticle portion of the contrast agent.
These data, combined with the linker studies, strongly
suggest that the major contribution to levels of
Tf-SC-CLIO probe accumulated within the cells is due to
linkage-dependent changes in the overall interaction and
processing of the probe by the cells.
Over the years, significant literature has described the use
of 67Ga for imaging of cancers by the TfR, but only limited
successes have been reported with most successes reported
for the detection of lymphomas [32,33]. However, there are
several factors that do not affect the MR probe technology
presented here, but may limit 67Ga imaging of the TfR. First,
67Ga must bind to Tf for uptake into cells by the TfR [34–37]
and, depending on the iron status of the patient, this will vary.
Second, 67Ga accumulates poorly within cells at a rate that is
one-sixth that of ferric iron [38]. Therefore, it is likely that the
recycling of the TfR causes significant efflux of internalized
67Ga, limiting the radiolabel accumulation and the resulting
signal that can be detected. The technology presented here
does not suffer from either of these limitations as the imaging
agent is conjugated to holotransferrin chemically prior to
administration and the multivalency of the probe causes
rerouting and vesicular accumulation of the imaging probe in
cells.
To enhance the detection of small tumors, our laboratory
has hypothesized that identification of imagable markers will
significantly amplify the diagnostic potential of conventional
imaging modalities. Our initial work demonstrated both in
vitro and in vivo that MRI can be significantly improved if iron
oxide nanoparticles are targeted to cell surface receptors
that are overexpressed in the malignant state. However, data
describing the expression patterns of such imagable markers
are limited, often only reported in the literature for a few
samples or qualitatively. We have now begun to identify
imagable molecular markers for disease progression. Using
laser capture microdissection and RT-Q-PCR, we have been
able to measure the expression of these markers in matched
normal and diseased tissues from patients. These studies
have demonstrated that the TfR is five-fold or more overex-
pressed in 41% of cancers in our patient population and in
even a greater percentage, 45%, of invasive breast cancers.
This differential is imagable using the technologies described
here. Taken together, the data presented here suggest that,
although the TfR is not suitable as a stand-alone diagnostic
marker, if TfR-specific probes were clinically available, they
potentially would increase the sensitivity of MR for detection
of small breast tumors in over 40% of cases. We are
currently extending this analysis to include the larger family
of internalizing receptors to determine the expression pro-
files of these imagable markers in cancers.
The work presented here has demonstrated that better
understanding of imaging biology can significantly influence
Figure 9. Overexpression of endogenous human TfR in human breast cancer tissues and matched normal. Breast cancers from 27 different patients were
microdissected and RNA was linearly amplified. Following amplification, the level of TfR mRNA was measured in RNA derived from matched normal, DCIS, or
invasive cancer. Presented data report fold-change in TfR levels in either DCIS or invasive cancer, relative to matched normal breast tissue samples. Sample
numbers are listed outside of the plot frame (INV = invasive ductal carcinoma, IS = ductal carcinoma in situ).
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the design, synthesis, and efficacy ofMRI probes.We hope to
increase our knowledge of TfR and other internalizing recep-
tors by exploiting phage display to interrogate biology and
design imaging probes that will be targeted based on peptide
binding to selected sites contained within the receptors.
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